Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial - PubMed (original) (raw)
Clinical Trial
Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial
Giulio Marchesini et al. Gastroenterology. 2003 Jun.
Abstract
Background & aims: The role of oral supplementation with branched-chain amino acids (BCAA) in advanced cirrhosis is far from settled. A nutritional approach might prevent progressive liver failure and improve nutritional parameters and quality of life.
Methods: A multicenter, randomized study comparing 1-year nutritional supplementation with BCAA against lactoalbumin or maltodextrins was performed in 174 patients with advanced cirrhosis. Primary outcomes were the prevention of a combined end point (death and deterioration to exclusion criteria), the need for hospital admission, and the duration of hospital stay. Secondary outcomes were nutritional parameters, laboratory data and Child-Pugh score, anorexia, health-related quality of life, and need for therapy.
Results: Treatment with BCAA significantly reduced the combined event rates compared with lactoalbumin (odds ratio, 0.43; 95% confidence interval, 0.19-0.96; P = 0.039) and nonsignificantly compared with maltodextrins (odds ratio, 0.51; 95% confidence interval, 0.23-1.17; P = 0.108). The average hospital admission rate was lower in the BCAA arm compared with control treatments (P = 0.006 and P = 0.003, respectively). In patients who remained in the study, nutritional parameters and liver function tests were, on average, stable or improved during treatment with BCAA and the Child-Pugh score decreased (P = 0.013). Also, anorexia and health-related quality of life (SF-36 questionnaire) improved. Long-term compliance with BCAA was poor.
Conclusions: In advanced cirrhosis, long-term nutritional supplementation with oral BCAA is useful to prevent progressive hepatic failure and to improve surrogate markers and perceived health status. New formulas are needed to increase compliance.
Comment in
- Branched-chain amino acid-enriched supplements as therapy for liver disease: Rasputin lives.
Charlton M. Charlton M. Gastroenterology. 2003 Jun;124(7):1980-2. doi: 10.1016/s0016-5085(03)00550-x. Gastroenterology. 2003. PMID: 12806634 No abstract available.
Similar articles
- Effects of Branched-Chain Amino Acid (BCAA) Supplementation on the Progression of Advanced Liver Disease: A Korean Nationwide, Multicenter, Prospective, Observational, Cohort Study.
Park JG, Tak WY, Park SY, Kweon YO, Chung WJ, Jang BK, Bae SH, Lee HJ, Jang JY, Suk KT, Oh MJ, Heo J, Woo HY, Jang SY, Lee YR, Lee JS, Kim DY, Kim SH, Suh JI, Kim IH, Kang MK, Lee WK. Park JG, et al. Nutrients. 2020 May 15;12(5):1429. doi: 10.3390/nu12051429. Nutrients. 2020. PMID: 32429077 Free PMC article. - Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis.
Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H; Long-Term Survival Study Group. Muto Y, et al. Clin Gastroenterol Hepatol. 2005 Jul;3(7):705-13. doi: 10.1016/s1542-3565(05)00017-0. Clin Gastroenterol Hepatol. 2005. PMID: 16206505 Clinical Trial. - Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis.
Hayaishi S, Chung H, Kudo M, Ishikawa E, Takita M, Ueda T, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ueshima K. Hayaishi S, et al. Dig Dis. 2011;29(3):326-32. doi: 10.1159/000327571. Epub 2011 Aug 9. Dig Dis. 2011. PMID: 21829025 - Branched-chain amino acid enriched supplements as therapy for liver disease.
Charlton M. Charlton M. J Nutr. 2006 Jan;136(1 Suppl):295S-8S. doi: 10.1093/jn/136.1.295S. J Nutr. 2006. PMID: 16365102 Review. - Branched-chain amino acids as pharmacological nutrients in chronic liver disease.
Kawaguchi T, Izumi N, Charlton MR, Sata M. Kawaguchi T, et al. Hepatology. 2011 Sep 2;54(3):1063-70. doi: 10.1002/hep.24412. Epub 2011 Jun 23. Hepatology. 2011. PMID: 21563202 Review.
Cited by
- Optimizing muscle preservation during weight loss in patients with cirrhosis: A pilot study comparing continuous energy restriction to alternate-day modified fasting for weight loss in patients with obesity and non-alcoholic cirrhosis of the liver.
Dunn W, Herrmann SD, Montgomery RN, Hastert M, Honas JJ, Rachman J, Donnelly JE, Steger FL. Dunn W, et al. Obes Sci Pract. 2024 Oct 24;10(5):e70016. doi: 10.1002/osp4.70016. eCollection 2024 Oct. Obes Sci Pract. 2024. PMID: 39450267 Free PMC article. - Branched-chain amino acids alleviate NAFLD via inhibiting de novo lipogenesis and activating fatty acid β-oxidation in laying hens.
Jian H, Li R, Huang X, Li J, Li Y, Ma J, Zhu M, Dong X, Yang H, Zou X. Jian H, et al. Redox Biol. 2024 Nov;77:103385. doi: 10.1016/j.redox.2024.103385. Epub 2024 Oct 3. Redox Biol. 2024. PMID: 39426289 Free PMC article. - Adverse Events in Targeted Therapy for Unresectable Hepatocellular Carcinoma Predict Clinical Outcomes.
Imai K, Takai K, Aiba M, Unome S, Miwa T, Hanai T, Suetsugu A, Shimizu M. Imai K, et al. Cancers (Basel). 2024 Sep 14;16(18):3150. doi: 10.3390/cancers16183150. Cancers (Basel). 2024. PMID: 39335121 Free PMC article. - Mendelian randomization identifies causal associations between GWAS-associated bacteria and their metabolites and rheumatoid arthritis.
Zhou D, Jiao W, Shi W, Wang Q, Chen M. Zhou D, et al. Front Microbiol. 2024 Sep 2;15:1431367. doi: 10.3389/fmicb.2024.1431367. eCollection 2024. Front Microbiol. 2024. PMID: 39286352 Free PMC article. - Branched-Chain Amino Acids in Liver Diseases: Complexity and Controversy.
Zhang Y, Zhan L, Zhang L, Shi Q, Li L. Zhang Y, et al. Nutrients. 2024 Jun 14;16(12):1875. doi: 10.3390/nu16121875. Nutrients. 2024. PMID: 38931228 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical